Gilead Sciences (GILD) News Today $109.11 +2.95 (+2.78%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GILD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tema Etfs LLC Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Tema Etfs LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,846 shares of the biopharmaceutical company's stock, valMay 20 at 6:16 AM | marketbeat.comToronto Dominion Bank Buys 70,551 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Toronto Dominion Bank grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 710,523 shares of the biopharmaceutical company'May 20 at 6:07 AM | marketbeat.comSnowden Capital Advisors LLC Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Snowden Capital Advisors LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 67.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,948 shares of the biopharmaceutical cMay 20 at 5:58 AM | marketbeat.comGilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHAMay 19 at 11:09 PM | finance.yahoo.comSarissa Capital Management LP Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Sarissa Capital Management LP lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 65.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 262,080 shares of the biopharmaceutical company's stock after selling 501,253 shares durinMay 19 at 7:14 AM | marketbeat.comPathstone Holdings LLC Purchases 3,677 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Pathstone Holdings LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,725 shares of the biopharmaceutical company's stock aftMay 19 at 5:27 AM | marketbeat.comGilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHAMay 18 at 3:49 PM | insidermonkey.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Shell Asset Management Co.Shell Asset Management Co. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 66,635 shares of the biopharmaceutical company's stock aftMay 18 at 7:47 AM | marketbeat.comRoyal Bank of Canada Has $801.66 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Royal Bank of Canada boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,678,751 shares of the biopharmaceutical company's stock after acquiring an additional 2,005,863May 18 at 6:55 AM | marketbeat.com2 Dividend Stocks That are Holding Their Own in 2025May 17, 2025 | 247wallst.comPoint72 Europe London LLP Has $6.51 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Point72 Europe London LLP reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,494 shares of the biopharmaceutical company's stock afterMay 17, 2025 | marketbeat.comPoint72 Hong Kong Ltd Makes New $11.16 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD)Point72 Hong Kong Ltd bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 120,867 shares of the biopharmaceutical company'sMay 17, 2025 | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)ProShare Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,646,698 shares of the biopharmaceutical company's stock after buying anMay 17, 2025 | marketbeat.comQuantinno Capital Management LP Acquires 58,305 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Quantinno Capital Management LP lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 71.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,925 sharesMay 17, 2025 | marketbeat.comNorthRock Partners LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)NorthRock Partners LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 280.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,207 shares of the biopharmaceutical company's stock afterMay 17, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Nuveen Asset Management LLCNuveen Asset Management LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,208,321 shares of the biopharmaceuMay 17, 2025 | marketbeat.comSen. John Boozman Sells Gilead Sciences, Inc. (NASDAQ:GILD) SharesMay 17, 2025 | americanbankingnews.comSen. John Boozman Sells Gilead Sciences, Inc. (NASDAQ:GILD) StockSenator John Boozman (R-Arkansas) recently sold shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on May 14th, the Senator disclosed that they had sold between $1,001 and $15,000 in Gilead Sciences stock on April 16th. Senator John Boozman also recently made the following trade(sMay 17, 2025 | marketbeat.comInsider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD)May 16, 2025 | gurufocus.comMorgens Waterfall Vintiadis & Co. Inc. Makes New $3.70 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD)Morgens Waterfall Vintiadis & Co. Inc. acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,000 shares oMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $34.62 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Parkman Healthcare Partners LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 190.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 374,825 shares of the biopharmaceutical compaMay 16, 2025 | marketbeat.comMufg Securities Americas Inc. Buys New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)Mufg Securities Americas Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,397 shares of the biopharmaMay 16, 2025 | marketbeat.comMan Group plc Purchases 243,567 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Man Group plc grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 873,179 shares of the biopharmaceutical company's stock after purchasing an additional 243,May 16, 2025 | marketbeat.comNia Impact Advisors LLC Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)Nia Impact Advisors LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,400 shares of the biopharmaceutical company's stock after selling 1May 16, 2025 | marketbeat.comNissay Asset Management Corp Japan ADV Acquires 14,009 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Nissay Asset Management Corp Japan ADV increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 284,243 shares of the biopharmaceutical compMay 16, 2025 | marketbeat.comNan Shan Life Insurance Co. Ltd. Sells 492,590 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Nan Shan Life Insurance Co. Ltd. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 66.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 243,792 shares of the biophMay 16, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from AnalystsGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, fifteen have issuedMay 16, 2025 | marketbeat.comGilead Sciences Q1 Earnings TranscriptMay 15, 2025 | marketbeat.com43,908 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Mubadala Investment Co PJSCMubadala Investment Co PJSC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 43,908 shares of the biopharmaceutical company's stock, valued at approximately $4,056,000. Gilead SciencesMay 15, 2025 | marketbeat.com24,347 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Napa Wealth ManagementNapa Wealth Management bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 24,347 shares of the biopharmaceutical company's stock, valueMay 15, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 998,929 shares of the biopharMay 15, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Lazard Asset Management LLCLazard Asset Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 400,581 shares of the biopharmaceutical company's stock after selling 43,565 shares during the period.May 15, 2025 | marketbeat.comLMR Partners LLP Purchases Shares of 56,799 Gilead Sciences, Inc. (NASDAQ:GILD)LMR Partners LLP acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 56,799 shares of the biopharmaceutical company's stock, valued at approximately $5,247,000. SeveraMay 15, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by J. Goldman & Co LPJ. Goldman & Co LP reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 94.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,373 shares of the biopharmaceutical company's stock after selling 60,May 15, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,296,077 shares of the biopharmaceutical company's stockMay 15, 2025 | marketbeat.comFocus Partners Wealth Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Focus Partners Wealth boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 117,736 shares of the biopharmaceutical company's stock afMay 15, 2025 | marketbeat.comGilead Sciences Is Overvalued Now (Rating Downgrade)May 14, 2025 | seekingalpha.comLetko Brosseau & Associates Inc. Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Letko Brosseau & Associates Inc. cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 598,388 shares of the biophMay 14, 2025 | marketbeat.comIntegral Health Asset Management LLC Purchases Shares of 200,000 Gilead Sciences, Inc. (NASDAQ:GILD)Integral Health Asset Management LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 200,000 shares of tMay 14, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $59.89 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Jacobs Levy Equity Management Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 648,386 shares of the biopharmaceutical company's stock after purchasing an additionMay 14, 2025 | marketbeat.comGraham Capital Management L.P. Purchases Shares of 18,886 Gilead Sciences, Inc. (NASDAQ:GILD)Graham Capital Management L.P. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 18,886 shares of the biopharmaceutical company's stock, valued at apMay 14, 2025 | marketbeat.comGilead Sciences, Inc. (GILD) BofA Securities Health Care Conference TranscriptMay 13, 2025 | seekingalpha.comWhy Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing BoomMay 13, 2025 | msn.comQ2 EPS Estimates for Gilead Sciences Raised by AnalystGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for Gilead Sciences in a report released on Thursday, May 8th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn $1.93 per share forMay 13, 2025 | marketbeat.comGilead Sciences Q2 EPS Forecast Raised by Zacks ResearchMay 13, 2025 | americanbankingnews.comGilead Sciences Inc (GILD) Trading 7.04% Higher on May 12May 12, 2025 | gurufocus.comGilead Sciences, Inc. (NASDAQ:GILD) Position Trimmed by First Manhattan CO. LLC.First Manhattan CO. LLC. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,084 shares of the biopharmaceutical companyMay 12, 2025 | marketbeat.comIs Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?May 11, 2025 | insidermonkey.comEnsign Peak Advisors Inc Acquires 60,474 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Ensign Peak Advisors Inc lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,669,871 shares of the biopharmaceutical companyMay 11, 2025 | marketbeat.comEthic Inc. Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Ethic Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 104,644 shares of the biopharmaceutical company's stock after buying an additional 7,638 shares during the quMay 11, 2025 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼1.290.65▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼4530▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today EXEL News Today INCY News Today NBIX News Today BMRN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
